ReidNKJoynerKRLewis-WolfsonTD. Baricitinib versus tocilizumab for the treatment of moderate to severe COVID-19 [published online ahead of print October 29, 2022]. Ann Pharmacother.
2.
WHO Rapid Evidence Appraisal for COVID-19 Therapies Working Groupl; Shankar-HariMValeCL, et al. Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19: a meta-analysis. JAMA. 2021;326(6):499-518.
3.
SelvarajVFinnALalAKhanMSDapaah-AfriyieKCarinoGP. Baricitinib in hospitalised patients with COVID-19: a meta-analysis of randomised controlled trials. EClinicalMedicine. 2022;49:101489.
4.
KarampitsakosTPapaioannouOTsiriP, et al. Tocilizumab versus baricitinib in hospitalized patients with severe COVID-19: an open label, randomized controlled trial. Clin Microbiol Infect. 2022;29:372–378.
5.
AtallahBEl NekidyWMallahSI, et al. Thrombotic events following tocilizumab therapy in critically ill COVID-19 patients: a Façade for prognostic markers. Thromb J. 2020;18:22.
6.
ChanKHPatelBPodelB, et al. Tocilizumab and thromboembolism in COVID-19: a retrospective hospital-based cohort analysis. Cureus. 2021;13(5):e15208.
7.
NosakaMIshidaYKimuraA, et al. Crucial involvement of IL-6 in thrombus resolution in mice via macrophage recruitment and the induction of proteolytic enzymes. Front Immunol. 2020;10:3150.
RECOVERY Collaborative Group. Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet. 2021;397(10285):1637-1645.
10.
RoddyJWellsDSchenckKSantoshSSantoshS. Tocilizumab versus baricitinib in patients hospitalized with COVID-19 pneumonia and hypoxemia: a multicenter retrospective cohort study. Crit Care Explor. 2022;4(5):e0702.
